Amarin Corporation Plc (AMRN)
| Market Cap | 2.55B |
| Revenue (ttm) | 590.09M |
| Net Income (ttm) | -15.86M |
| Shares Out | 389.70M |
| EPS (ttm) | -0.04 |
| PE Ratio | n/a |
| Forward PE | 40.98 |
| Dividend | n/a |
| Dividend Yield | n/a |
| Trading Day | January 22 |
| Last Price | $6.55 |
| Previous Close | $6.31 |
| Change ($) | 0.24 |
| Change (%) | 3.80% |
| Day's Open | 6.59 |
| Day's Range | 6.34 - 6.63 |
| Day's Volume | 6,171,100 |
| 52-Week Range | 3.64 - 20.26 |
DUBLIN, Ireland and BRIDGEWATER, N.J., Jan. 21, 2021 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN) today announced that the Chinese Society of Cardiology (CSC) has included icosapen...
Investors holding shares in these two companies need to practice patience.
Amarin Corporation PLC (AMRN) CEO John Thero Presents at the 39th Annual JPMorgan Virtual Healthcare Conference (Transcript)
Unaudited 2020 Total Net Revenue Estimated to Be Approximately $610 Million, an Increase of Approximately 42% Compared with 2019
Down 77% in 2020, Amarin's stock should zoom higher once Vascepa obtains European approval.
DUBLIN, Ireland and BRIDGEWATER, N.J., Jan. 04, 2021 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN) announced today that John F. Thero, Amarin's president and chief executive officer...
Amarin (AMRN) saw a big move last session, as its shares jumped nearly 9% on the day, amid huge volumes.
These companies are eager to say good riddance to the year that was.
Biopharma deal-making is expected to pick up in 2021 after its slump in 2020, with a good example being AstraZeneca's (AZN) nearly $40 billion purchase of Alexion Pharmaceuticals (ALXN), which...
REDUCE-IT® EPA Encore Presentation reinforces Eicosapentaenoic Acid (EPA) levels from VASCEPA® (icosapent ethyl) strongly correlated to cardiovascular outcomes, more so than other biomarkers
VASCEPA COVID-19 CardioLink-9 Randomized Trial suggests improvement in patient-reported COVID-19 symptoms while achieving its primary endpoint by demonstrating a 25% reduction in high-sensitiv...
Investors need to pay close attention to Amarin (AMRN) stock based on the movements in the options market lately.
Amarin-Supported Research and Analyses from Academic Collaborators to Be Featured in Two Late Breaker and Six e-Poster Presentations, Including Encore of REDUCE-IT® EPA, Primary Results of the...
These are the stocks seeing the most insider buying this week
Brian Sullivan on the top companies this week whose executives are purchasing their own stock, on Worldwide Exchange.
Amarin Corporation plc (AMRN) CEO John Thero Presents at Piper Sandler 32nd Annual Virtual Healthcare Conference Call - (Transcript)
DUBLIN, Ireland and BRIDGEWATER, N.J., Nov. 30, 2020 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN), announced today the filing of a patent infringement lawsuit by Amarin affiliates ...
DUBLIN, Ireland and BRIDGEWATER, N.J., Nov. 24, 2020 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN) today announced that John F. Thero, Amarin's president and chief executive officer...
Amarin lost its generic appeal and the stock has faltered badly. People are possibly ignoring the vast European market and also what's left of the US market may be protected by manufacturing h...
Amarin's legal loss at the U.S. appeals court sent the stock lower. Positive clinical data from China partner a catalyst.
After Amarin lost its patent rights in the U.S., the stock crashed overnight. Investors might want to stay optimistic.
AMRN stock is climbing higher Thursday thanks to good news from a clinical trial in China. Here's what you should know about Amarin now.
Significant Reduction in Triglyceride Levels Without Low-Density Lipoprotein Cholesterol ( LDL-C ) Increase Compared to Placebo and Safety Profile Similar to Placebo Achieved with 4 Grams Per ...
Amarin Corporation PLC (AMRN) Presents at Jefferies Virtual London Healthcare Broker Conference Call - (Transcript)
Findings further support the differentiated multifactorial mechanism of action of VASCEPA and its robust clinical effective ness in reducing major adverse cardiovascular events (MACE) in studi...
Amarin Corporation plc (AMRN) Presents at Stifel Virtual Healthcare Conference (Transcript)
VASCEPA®, compared with placebo, significantly reduced primary composite first and total major adverse cardiovascular events ( MACE ) in post hoc exploratory analyses of patients with a histor...
DUBLIN, Ireland and BRIDGEWATER, N.J., Nov. 11, 2020 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN) today announced that John F. Thero, Amarin's president and chief executive officer...
Amarin's (AMRN) revenue growth in the third quarter is attributable to continued demand for its cardiovascular drug, Vascepa. Generic competition for Vascepa seems imminent.
Amarin Corporation plc (AMRN) CEO John Thero on Q3 2020 Results - Earnings Call Transcript
Total Revenue Increased 39 % in Third Quarter 2020 and 56% in First Nine Months of 2020 Compared to Same Periods of 2019 Despite COVID-19 Headwinds
Here's why the stock prices of Tesla, Zoom, and Amarin are being driven by overexuberant speculation.
The heart drug continues to test well in clinical trials.
Patients with decreased renal function prior to treatment with VASCEPA or placebo had higher rates of cardiovascular events than the overall population studied in REDUCE-IT
New analysis of contemporary real-world data presented at American Society of Nephrology (ASN) Kidney Week 2020 New analysis of contemporary real-world data presented at American Society of Ne...
The health care strategy analyst at Jefferies said he expects to see acquisitions in the pharma and biotech space in the $5 billion to $10 billion range, according to an article in FierceBiote...
DUBLIN, Ireland and BRIDGEWATER, N.J., Oct. 19, 2020 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN) today announced that it will host a conference call with members of Amarin senior ...
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Oct. 15)
VASCEPA ® , c ompared with placebo, significantly reduced primary composite first and total MACE (m ajor a dverse c ardiovascular e vents ) in post hoc exploratory analyses of patients with a ...
The stocks of Amarin and Clean Energy Fuels are down 90% off their highs -- but both could bounce back in a big way.
Investors need to pay close attention to Amarin (AMRN) stock based on the movements in the options market lately.
Data presented provides additional insight into potential mechanisms by which VASCEPA lowers cardiovascular risk Data presented provides additional insight into potential mechanisms by which V...
Amarin Corporation plc (AMRN) CEO John Thero Presents at Cantor Virtual Global Healthcare Conference (Transcript)
DUBLIN, Ireland and BRIDGEWATER, N.J., Sept. 09, 2020 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN) announced today that John F. Thero, Amarin's president and chief executive offi...
Amarin shares have taken a beating this week during the appellate hearing and especially after the adverse ruling came down on September 3.
Amarin (AMRN) receives a setback as the U.S. Court of Appeals upholds a ruling by Nevada district court in favor of the generic companies related to patent litigation against Vascepa.
Just one day after hearing arguments, the U.S. Court of Appeals delivered a ruling that Amarin shareholders did not want to hear.
DUBLIN, Ireland and BRIDGEWATER, N.J., Sept. 03, 2020 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN) today provided an update following the decision by the U.S. Court of Appeals fo...
Amarin's Vascepa Data, And Other News: The Good, Bad And Ugly Of Biopharma
Los Angeles, California--(Newsfile Corp. - September 2, 2020) - The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of inve...
Peloton, Docusign, MongoDB, Amarin and SmileDirectClub were our top stock trades for Thursday. So, let's take a closer look at the charts.
About AMRN
Amarin Corporation plc, a pharmaceutical company, develops and commercializes therapeutics for the treatment of cardiovascular diseases in the United States. The company's lead product is Vascepa, a prescription-only omega-3 fatty acid capsule, used as an adjunct to diet for reducing triglyceride levels in adult patients with severe hypertriglyceridemia. It is also involved in developing REDUCE-IT for the treatment of patients with high triglyceride levels who are also on statin therapy for elevated low-density lipoprotein cholesterol levels. T... [Read more...]
| Industry Biotechnology | IPO Date Apr 1, 1993 |
| CEO John Thero | Employees 965 |
| Stock Exchange NASDAQ | Ticker Symbol AMRN |
Financial Performance
In 2019, Amarin's revenue was $429.76 million, an increase of 87.49% compared to the previous year's $229.21 million. Losses were -$22.65 million, -80.55% less than in 2018.
Analyst Forecasts
According to 12 analysts, the average rating for Amarin stock is "Buy." The 12-month stock price forecast is 10.00, which is an increase of 52.67% from the latest price.